Outlook Therapeutics Files 8-K with Key Corporate Updates

TL;DR

Outlook Therapeutics filed an 8-K on Jan 16, 2025, detailing material agreements, equity sales, and security holder changes.

AI Summary

Outlook Therapeutics, Inc. filed an 8-K on January 16, 2025, reporting on several events including the entry into a material definitive agreement, unregistered sales of equity securities, and material modifications to security holder rights. The filing also covers other events and financial statements/exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions and potential changes in the company's structure or financial standing, which could impact investors and stakeholders.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity securities and material modifications to security holder rights, which can introduce uncertainty and potential dilution.

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — Registrant
• January 16, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-37759 (company_id) — Commission File Number
• 38-3982704 (tax_id) — IRS Employer Identification No.
• 111 S. Wood Avenue Unit #100 (address) — Business address
• Iselin, New Jersey 08830 (address) — Business address city, state, zip

FAQ

Key Financial Figures

• $0.01 — e the Company's common stock, par value $0.01 per share (the "Common Stock"), exercis
• $2.51 — Warrants at a reduced exercise price of $2.51 per share (which includes $0.125 per In
• $0.125 — rice of $2.51 per share (which includes $0.125 per Inducement Warrant (as defined belo
• $2.26 — rrant Shares"), at an exercise price of $2.26 per share. The Inducement Warrants will
• $17.8 m — the Existing Warrants are approximately $17.8 million, before deducting capital markets
• $8.7 million — Reduced Exercise Price of approximately $8.7 million in exchange for Inducement Warrants to
• $2.7 m — rrants are expected to be approximately $2.7 million, before deducting capital markets

Filing Documents

• tm253522d1_8k.htm (8-K) — 55KB
• tm253522d1_ex4-1.htm (EX-4.1) — 103KB
• tm253522d1_ex4-2.htm (EX-4.2) — 103KB
• tm253522d1_ex4-3.htm (EX-4.3) — 103KB
• tm253522d1_ex4-4.htm (EX-4.4) — 103KB
• tm253522d1_ex10-1.htm (EX-10.1) — 70KB
• tm253522d1_ex10-2.htm (EX-10.2) — 78KB
• 0001104659-25-004159.txt ( ) — 933KB
• otlk-20250116.xsd (EX-101.SCH) — 3KB
• otlk-20250116_lab.xml (EX-101.LAB) — 34KB
• otlk-20250116_pre.xml (EX-101.PRE) — 22KB
• tm253522d1_8k_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. Warrant Inducement On January 16, 2025, Outlook Therapeutics, Inc. (the "Company") entered into warrant exercise inducement offer letter agreements (each an "Inducement Letter" and together, the "Inducement Letters") with certain holders (each a "Holder" and collectively, the "Holders") of existing warrants to purchase the Company's common stock, par value $0.01 per share (the "Common Stock"), exercisable for an aggregate of 7,074,637 shares of Common Stock (collectively, the "Existing Warrants"), pursuant to which the Holders agreed to exercise their Existing Warrants at a reduced exercise price of $2.51 per share (which includes $0.125 per Inducement Warrant (as defined below)) (the "Reduced Exercise Price"), in exchange for the Company's agreement to issue new warrants to purchase Common Stock (the "Inducement Warrants") as described below. The reduction of the exercise price of the Existing Warrants and the issuance of the Inducement Warrants was structured as an at-market transaction under Nasdaq rules. The shares of common stock issuable upon exercise of the Existing Warrants are registered for issuance pursuant to Registration Statement on Form S-3 (File No. 333-278209), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 1, 2024. In consideration for the immediate exercise of the Existing Warrants for cash at the Reduced Exercise Price, the Holders will receive two Inducement Warrants for each Existing Warrant exercised. The Inducement Warrants will be exercisable for an aggregate of up to 14,149,274 shares of Common Stock (the "Inducement Warrant Shares"), at an exercise price of $2.26 per share. The Inducement Warrants will only be exercisable for cash, except in limited circumstances. A Holder may not exercise the Inducement Warrants if the Holder, together with its affiliates, would beneficially own more than a specified percentage of the outstanding Comm

02

Item 3.02 Unregistered Sales of Equity Securities. The information contained above in Item 1.01 relating to the warrant inducement is hereby incorporated by reference into this Item 3.02. The Inducement Warrants and Syntone Inducement Warrants are being sold and, upon exercise the Inducement Warrant Shares and Syntone Inducement Warrant Shares, will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. The Holders made relevant representations in their respective Inducement Letters. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of common stock or other securities of the Company.

03

Item 3.03 Material Modification to Rights of Security Holders. The disclosure under Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.

01

Item 8.01 Other Events. On January 16, 2025, the Company issued a press release announcing it has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two adequate and well controlled clinical trials evaluating ONS-5010 in wet age-related macular degeneration ("AMD") patients. ONS-5010 demonstrated noninferiority to ranibizumab at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, the Company plans to resubmit the Biologics License Application ("BLA") for ONS-5010 in the first quarter of calendar 2025. The difference in the mean between ONS-5010 and ranibizumab was -1.009 best corrected visual acuity ("BCVA") letters with a 95% confidence interval of (-2.865, 0.848) in the NORSE EIGHT trial. Applying the statistical parameters from the week 8 primary endpoint with the lower bound of the non-inferiority margin at -3.5 with a 95% confidence interval, the noninferiority margin was met at week 12 (p=0.0043), indicating that the two study arms are not different at this timepoint. In the intent-to-treat ("ITT") population, NORSE EIGHT demonstrated a mean 5.5 letter improvement in BCVA in the ONS-5010 arm and 6.5 letter improvement in BCVA in the ranibizumab arm. Mean change in BCVA at week 12 Non-Inferiority ONS-5010 1.25 mg +5.5 letters 95%CI: (-2.865, 0.848) P-value: 0.0043 Ranibizumab 0.5mg +6.5 letters Additionally, the change in central retinal thickness, a measure of anatomical response, was similar in both study arms at all three study timepoints. Mean change in central retinal thickness Week 4 Week 8 Week 12 ONS-5010 1.25 mg -106.6 microns -117.7 microns -123.9 microns Ranibizumab 0.5mg -108.4 microns -120.9 microns -127.3microns As previously announced, in the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the U.S. Food and Drug Administra

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking "intend," "may," "will," "would," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. All statements other than from the warrant inducement and Syntone warrant inducement transactions and the use thereof, the potential of obtaining the Requisite Stockholder Approval for the Share Increase Proposal, the Company's plans to file resale registration statements to register the resale of the Warrant Inducement Shares and Syntone Warrant Inducement Shares and the Company's plans and timing thereof to resubmit a BLA for ONS-5010. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this Current Report on Form 8-K. These forward-looking statements are subject to risks and uncertainties that could cause results and events to differ significantly from those expressed or implied by the forward-looking statements, including risks associated with closing a securities offering. Additional factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking including under "Risk Factors" in the Company's annual report on Form 10-K for the year ended September 30, 2023 and future filings by the Company. Except as required by law, the Company assumes no obligati

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 4.1 Form of Tranche A Inducement Warrant. 4.2 Form of Tranche B Inducement Warrant. 4.3 Form of Syntone Tranche A Inducement Warrant. 4.4 Form of Syntone Tranche B Inducement Warrant. 10.1 Form of Inducement Letter. 10.2 Form of Syntone Inducement Letter. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: January 16, 2025 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR